clinical trial · NCT06101342
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
Gilead Sciences·phase2·active not recruiting·n = 181
Pre-Exposure Prophylaxis of HIV InfectionLenacapavir InjectionLenacapavir TabletEmtricitabine/tenofovir disoproxil fumarate (F/TDF)
brief summary
The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.
started
Dec 13, 2023
primary completion
Jan 1, 2028
completion
Jan 1, 2028
last updated
Mar 2, 2026
official title
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol